Glenzocimab

格仑西单抗

Report date: 2023/09/11 17:53:02

Base Information

Drug NameGlenzocimab
Drug Alias NameACT-017ACT017
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionPlatelet membrane glycoprotein VI inhibitors
TargetsPlatelet membrane glycoprotein VI
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic StrokeHeart Diseases +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesActicor Biotech
China Registration ClassN/A

Develop Information

Active CompaniesChina Medical System Holdings LtdActicor BiotechUniversity Of Birmingham +[4] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic StrokeHeart Diseases +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG